arrow
A

Arnold B. Etame

Moffitt Cancer Center
H指数:34
被引数:4,415

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrative Single-Cell and Radiomics Analyses Identify N-Acetylneuraminate Synthase (NANS)-High Signature Associated with Adverse Prognosis and Immune Remodeling in Glioblastoma

整合单细胞和放射组学分析识别与胶质母细胞瘤不良预后和免疫重塑相关的N-乙酰神经氨酸合酶(NANS)高表达特征

2026-10-290
OA
52 FGD1 Splice Variant in Clear Cell Renal Cell Carcinoma is a Novel Biomarker for Inferior Clinical Outcomes and Development of Brain and Bone Metastases

52 透明细胞肾细胞癌中的FGD1剪接变体是预测不良临床结局和脑骨转移发生的新的生物标志物

2026-09-020
OAAI
RNF135 Expression Marks Chemokine (C-C Motif) Ligand-Enriched Macrophage–Tumor Interactions in the Glioblastoma Microenvironment

陈, J.; 吴, Q.; Berglund, A.E.; Macaulay, R.J.; Mule, J.J.; Etame, A.B. RNF135 表达标记胶质瘤微环境中趋化因子(C-C基序)配体富集的巨噬细胞-肿瘤相互作用。Cancers 2025, 17, 3271. [Google Scholar] [CrossRef] [PubMed]

Cancers
IF4.4
2026-03-030
OAAI
Evaluating the current neuro-oncology capacity in Sub-Saharan Africa: A questionnaire-based survey
2026-02-010
PRE
Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study

Nivolumab和立体定向放射外科治疗乳腺癌脑转移患者:一项非随机、开放标签、Ib期研究的长期结果和生物标志物分析

2025-04-280
OA
Phase 1 trial of hypofractionated stereotactic re-irradiation in combination with nivolumab, ipilimumab, and bevacizumab for recurrent high-grade gliomas
2025-02-080
OAAI
Establishment of a brain tumor consortium of Africa: Advancing collaborative research and advocacy for brain tumors in Africa
2024-11-161
OAAI